Michael E. Ivan

Michael E. Ivan

Auto-generated profile, based on publicly available information

Michael E. Ivan

Department of Neurological Surgery, University of Miami Miller School of Medicine, Miami, Florida, USA

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 November 2019 in Neurosurgery
Verified
Journal Article
Closed access
Ashish H. ShahAshish H. Shah
Ashish H. Shah
ASAlexa Semonche
Alexa Semonche
DEDaniel G Eichberg
Daniel G Eichberg
VBVeronica Borowy
Veronica Borowy
ELEvan Luther
Evan Luther
RKRicardo J Komotar
Ricardo J Komotar
BACKGROUND: Laser interstitial thermal therapy (LITT) is an adjuvant treatment for intracranial lesions that are treatment refractory or in deep or eloquent brain. Initial studies of LITT in surgical neuro-oncology are limited in size and follow-up. OBJECTIVE: To present our series of LITT in surgical neuro-oncology to better evaluate procedural safety and outcomes. METHODS: An exploratory cohort study of all patients receiving LITT for brain tumors by a single senior neurosurgeon at a single center between 2013 and 2018. Primary outcomes included extent of ablation (EOA), time to recurrence (TTR), local control at 1-yr follow-up, and overall survival (OS). Secondary outcomes included complication rate. Outcomes were compared by tumor subtype. Predictors of outcomes were identified. RESULTS: A total of 91 patients underwent 100 LITT procedures; 61% remain alive with 72% local control at median 7.2 mo follow-up. Median TTR and OS were 31.9 and 16.9 mo, respectively. For lesion subtypes, median TTR (months, not applicable [N/A] if 85% predicted longer TTR (P = .006, log-rank analysis). Complication rate was 4%. CONCLUSION: Our series of LITT in surgical neuro-oncology, 1 of the largest to date, further evidences its safety and outcomes profile.

1 July 2020 in World Neurosurgery
Verified
Journal Article
Closed access
LDLekhaj C. Daggubati
Lekhaj C. Daggubati
DEDaniel G. Eichberg
Daniel G. Eichberg
MIMichael E. Ivan
Michael E. Ivan
SHSimon Hanft
Simon Hanft
AMAlireza Mansouri
Alireza Mansouri
BZBrad E. Zacharia
Brad E. Zacharia

1 December 2020 in World Neurosurgery
Verified
Journal Article
Closed access
AJAria M Jamshidi
Aria M Jamshidi
DEDaniel G. Eichberg
Daniel G. Eichberg
RKRicardo J. Komotar
Ricardo J. Komotar
MIMichael Ivan
Michael Ivan

1 December 2020 in World Neurosurgery
Verified
Journal Article
Closed access
SMSamuel Mansour
Samuel Mansour
ELEvan Luther
Evan Luther
NENikolas Echeverry
Nikolas Echeverry
DMDavid McCarthy
David McCarthy
DEDaniel G. Eichberg
Daniel G. Eichberg
JMJacques Morcos
Jacques Morcos

3 July 2019 in Neuro-Oncology Practice
Verified
Journal Article
Closed access
PDF file
Ashish H. ShahAshish H. Shah
Ashish H. Shah
AMAnil K Mahavadi
Anil K Mahavadi
AMAlexis Morell
Alexis Morell
DEDaniel G Eichberg
Daniel G Eichberg
ELEvan Luther
Evan Luther
RKRicardo J Komotar
Ricardo J Komotar
The incidence of symptomatic radiation necrosis (RN) has risen as radiotherapy is increasingly used to control brain tumor progression. Traditionally managed with steroids, symptomatic RN can remain refractory to medical treatment, requiring surgical intervention for control. The purpose of our study was to assess a single institution’s experience with craniotomy for steroid-refractory pure RN. The medical records of all tumor patients who underwent craniotomies at our institution from 2011 to 2016 were retrospectively reviewed for a history of preoperative radiotherapy or radiosurgery. RN was confirmed histopathologically and patients with active tumor were excluded. Preoperative, intraoperative, and outcome information was collected. Primary outcomes measured were postoperative KPS and time to steroid freedom. Twenty-four patients with symptomatic RN were identified. Gross total resection was achieved for all patients. Patients with metastases experienced an increase in KPS (80 vs 100, P < .001) and required a shortened course of dexamethasone vs patients with high-grade gliomas (3.4 vs 22.2 weeks, P = .003). RN control and neurological improvement at 13.3 months’ follow-up were 100% and 66.7%, respectively. Adrenal insufficiency after rapidly tapering dexamethasone was the only morbidity (n = 1). Overall survival was 93.3% (14/15) at 1 year. In cases of treatment-refractory symptomatic RN, resection can lead to an overall improvement in postoperative health status and neurological outcomes with minimal RN recurrence. Craniotomy for surgically accessible RN can safely manage symptomatic patients, and future studies assessing the efficacy of resection vs bevacizumab may be warranted.

1 February 2021 in World Neurosurgery
Verified
Journal Article
Closed access
GBGregory W. Basil
Gregory W. Basil
DEDaniel G. Eichberg
Daniel G. Eichberg
MPMaggy Perez-Dickens
Maggy Perez-Dickens
IMIngrid Menendez
Ingrid Menendez
MIMichael E. Ivan
Michael E. Ivan
UMUniversity of Miami Miller School of Medicine
University of Miami Miller School of Medicine